Study on the effectiveness of allergen immunotherapy in patients with house dust mite-induced allergic rhinitis and other associated allergic conditions

Effectiveness of allergen-specific sublingual immunotherapy for house dust mite-induced allergic rhinitis and its co-morbid conditions

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN32263767

Enrollment

120

Registered

2019-05-14

Start date

2019-03-01

Completion date

Unknown

Last updated

2019-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

House dust mite induced allergic diseases Injury, Occupational Diseases, Poisoning

Interventions

Patients diagnosed to have house dust mite-induced perennial allergic rhinitis according to ARIA guidelines who received sublingual immunotherapy (SLIT) with sublingual allergen extract for over 12 mo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Suffering from house dust mite-induced perennial allergic rhinitis.

Exclusion criteria

Exclusion criteria: 1. Incomplete records of clinical data. 2. Concurrent systemic immunological disorders. 3. Using immunomodulatory treatment.

Design outcomes

Primary

Measure	Time frame
Symptom scores are measured using a standardized questionnaire at baseline and then every 3 months.	—

Secondary

Measure	Time frame
Medication use is measured using a standardized questionnaire at baseline and then every 3 months.	—

Countries

Hong Kong

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026